Pharma Company Expands Capabilities with New Peptide Research Center
The company's Price-Earnings (PE) Ratio stands at 165.54.
Sai Life Sciences Limited has inaugurated a new Peptide Research Center at its R&D campus in Hyderabad, India. This strategic move aims to enhance the company's capabilities in peptide synthesis and conjugation, reflecting the evolving pharmaceutical landscape towards emerging modalities like peptides. Krishna Kanumuri, CEO & Managing Director, emphasized the company's commitment to advancing next-generation therapeutics, stating, "Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation."
The facility is equipped with automation, advanced liquid handling, robotics, and high-throughput systems, which will improve precision, scalability, and efficiency in developing novel peptide-based therapeutics. Maneesh Pingle, Head of Discovery Services, highlighted the rising demand for peptide-based therapeutics due to their high specificity and biocompatibility. The centre will integrate with Sai Life Sciences' end-to-end discovery services, ensuring seamless transitions across drug discovery stages, thereby accelerating timelines and enhancing success rates for peptide-based drug development. This initiative strengthens Sai Life Sciences' role as a trusted partner for global clients in advancing innovative peptide therapeutics.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
Sai Life Sciences Limited, established in 1999, is a Hyderabad-based contract research, development, and manufacturing organization (CRDMO) serving the pharmaceutical and biotechnology sectors. The company provides integrated services across the pharmaceutical lifecycle, from discovery to the development and manufacturing of new chemical entities. In FY24, Sai Life Sciences completed over 200 discovery programs, with more than 40 advancing to clinical phases.
The company boasts a comprehensive in-house capability in synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics, and toxicology. It serves 17 of the top 20 global pharmaceutical companies, with a significant presence in the US and European regulatory markets. The company's revenue is primarily derived from contract development and manufacturing (66 per cent) and contract research (34 per cent), with exports contributing 98 per cent of sales. Sai Life Sciences has expanded its DMPK capabilities with a new 25,000 sq. ft. lab, enhancing its service offerings. The company went public with an IPO, raising Rs 3,042.62 crore, and was listed on December 18, 2024.
Sai Life Sciences Limited has a market capitalization of Rs 15,536 crore. The company's Price-Earnings (PE) Ratio stands at 165.54. Major public shareholders include Tpg Asia Vii Sf Pte Ltd with 24.78 per cent, HBM Private Equity India with 1.99 per cent, Anitha Rudraraju Nandyala with 1.73 per cent, Raju Penmasta with 1.11 per cent and Penmasta Aruna with 1.02 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.